Global Minimally Invasive Surgical Devices Market to Witness Upsurge in Growth at a CAGR of ~7% by 2034 | DelveInsight
Best ETFs to Invest In, According to AI Analyst, 3/11/2026
What Happens to Dividend Income When the Next Recession Hits
Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $274
Express News | J&J: CEO 2025 Total Compensation $32.8 Mln- SEC Filing
Citigroup Adjusts Price Target on Johnson & Johnson to $274 From $250, Maintains Buy Rating
Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
Private credit remains under pressure, with redemption requests for a $33 billion fund potentially exceeding 7%.
The Cliffwater Corporate Lending Fund, which manages approximately USD 33 billion in assets, is a fund with periodic redemption terms. If redemption requests reach 5%, it must return 5% of the fund's value to investors on a quarterly basis. If redemption requests exceed 5%, Cliffwater has the authority to redeem up to 7% of the fund’s shares. According to media reports, the firm's flagship private credit fund may face redemption requests exceeding 7%.
My Top 3 Dividend Kings to Buy for March 2026
Johnson & Johnson Wins EU Approval for Akeega in BRCA-Mutated Prostate Cancer
Express News | Tecvayli®▼ (Teclistamab) Monotherapy Application Submitted to the EMA for Relapsed/Refractory Multiple Myeloma After at Least One Prior Therapy
Blackstone Balances Life Sciences Bet And REIT Interest As Valuation Lags
Johnson & Johnson Seeks Tecvayli Indication Extension in EU
Johnson & Johnson (JNJ) Announces the FDA Approval of TECVAYLI Plus DARZALEX FASPRO
Neurodegenerative Disease Devices Market to Witness Steady Growth Through 2032, Driven by Advanced Neuromodulation, Says Vyansa Intelligence
Express News | J&J - European Commission Approves Akeega for Brca1/2-Mutated Prostate Cancer
FDA Plans to Relax Testing Rules to Encourage Biosimilar Drugs: Report
2 No-Brainer Dividend Stocks to Buy in 2026
These 7 Elite Dividend Stocks Pay $114 Billion Annually, Combined, to Their Shareholders
FDA Vaccine Chief to Leave the Agency Again